文献速递血栓与止血

血栓性抗磷脂综合征的抗凝监测

Monitoring of anticoagulation in thrombotic antiphospholipid syndrome.
PubMed 文献 · J Thromb Haemost · 2021-02-20

综述总结血栓性抗磷脂综合征抗凝监测的常用检测、主要抗凝药物、狼疮抗凝物对监测试验的影响及个体化监测策略。标准治疗为终身华法林或替代维生素K拮抗剂,直接口服抗凝药作用未确立。准确评估抗凝强度对优化剂量、减少血栓复发或出血及指导特殊情境管理至关重要。

要点

  • 血栓性抗磷脂综合征标准抗凝为终身华法林或替代维生素K拮抗剂。
  • 狼疮抗凝物可影响磷脂依赖性凝血监测试验,可能不反映真实抗凝强度。
  • 特殊情境如严重肾损害、血小板减少、难治性APS及妊娠需考虑剂量与监测调整。

核心结论

  • 准确评估抗凝强度对优化血栓性抗磷脂综合征抗凝剂量、促进血栓溶解、减少复发血栓或出血风险至关重要。

研究设计与样本

  • 本文为综述,总结抗凝监测常用检测、血栓性抗磷脂综合征主要抗凝药物、狼疮抗凝物对监测试验的影响及监测策略。

主要发现

  • 血栓性抗磷脂综合征标准抗凝治疗为终身华法林或替代维生素K拮抗剂。
  • 直接口服抗凝药在血栓性抗磷脂综合征的作用因缺乏明确证据而未确立,近期国际指导文件已讨论。
  • 其他抗凝选择包括低分子量肝素、普通肝素和磺达肝癸钠。
  • 狼疮抗凝物可影响磷脂依赖性凝血监测试验,使其可能不反映真实抗凝强度。
  • 抗凝强度知识有助于评估复发血栓是否与突破性血栓、抗凝不足、不依从或假性结果相关。

临床怎么用

  • 血栓性抗磷脂综合征患者接受华法林或替代维生素K拮抗剂时需监测抗凝强度以优化剂量。
  • 狼疮抗凝物阳性时需注意磷脂依赖性凝血监测试验可能不反映真实抗凝强度。
  • APS相关严重肾损害、血小板减少、难治性APS及妊娠时需考虑抗凝剂量与监测调整。
  • 临床研究中需了解抗凝强度以评估和比较抗凝方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anticoagulation is central to the management of thrombotic antiphospholipid syndrome (APS). The standard anticoagulant treatment for thrombotic APS is life-long warfarin or an alternative vitamin K antagonist. The role of direct oral anticoagulants for thrombotic APS is not established due to the lack of definitive evidence and has recently been addressed in international guidance. Other anticoagulant options include low molecular weight heparin, unfractionated heparin, and fondaparinux. In APS patients, lupus anticoagulant can affect phospholipid-dependent coagulation monitoring tests, so that they may not reflect true anticoagulation intensity. Accurate assessment of anticoagulation intensity is essential, to optimize anticoagulant dosing and facilitate thrombus resolution; minimize the risk of recurrent thrombosis or bleeding; inform assessment of whether recurrent thrombosis is related to breakthrough thrombosis while on therapeutic anticoagulation, subtherapeutic anticoagulation, non-adherence, or spurious results; and guide the management of bleeding. Knowledge of anticoagulant intensity also informs assessment and comparison of anticoagulation regimens in clinical studies. Considerations regarding anticoagulation dosing and/or monitoring of thrombotic APS patients underpin appropriate management in special situations, notably APS-related severe renal impairment, which can occur in APS or APS/systemic lupus erythematosus-related nephropathy or catastrophic APS; and APS-related thrombocytopenia. Anticoagulant dosing and monitoring in thrombotic APS patients also require consideration in anticoagulant-refractory APS and during pregnancy. In this review, we summarize the tests generally used in monitoring anticoagulant therapy, use of the main anticoagulants considered for thrombotic APS, lupus anticoagulant effects on anticoagulation monitoring tests, and strategies for appropriate anticoagulant monitoring in thrombotic APS.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Cohen H, Efthymiou M, Devreese KMJ, et al. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. J Thromb Haemost. 2021. PMID: 33325604. doi:10.1111/jth.15217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。